NewAmsterdam Pharma Company NV NAMS
$27.87 $0.09 (0.32%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
NAMS Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, NewAmsterdam Pharma Company NV is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
NewAmsterdam Pharma Company NV. Stock Analysis NAMS
United States Health Care Mid Cap NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 100 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.
NewAmsterdam Pharma Company NV (NAMS) Chart
Financial Metrics & Statements of NewAmsterdam Pharma Company NV (NAMS)
FAQ's for NewAmsterdam Pharma Company NV (NAMS)
- As of August 2026, NewAmsterdam Pharma Company NV NAMS is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes NewAmsterdam Pharma Company NV using these criteria to determine its compliance status.
- Muslim investors may consider investing in NewAmsterdam Pharma Company NV if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of NewAmsterdam Pharma Company NV by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of NewAmsterdam Pharma Company NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of NewAmsterdam Pharma Company NV on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for NewAmsterdam Pharma Company NV (NAMS)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
